On the evening of June 3, Gloria Pharmaceutical(002437) issued an announcement stating that the company's wholly-owned subsidiary Tianjin Gloria Boda Technology Co., Ltd. (hereinafter referred to as "Tianjin Boda") and Eisai (China) Pharmaceuticals Co., Ltd. (hereinafter referred to as "Eisai China Pharmaceuticals") signed a "Marketing Service Agreement" for "Methylcobalamin Injection" (trade name: Mecobalamin).

The agreement stipulates that Eisai China Pharmaceuticals authorizes Tianjin Boda to exclusively promote methylcobalamin injection in mainland China (excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan), and the authorization period is from June 1 to the expiration date of the agreement. Tianjin Boda is responsible for providing marketing services and other related services for the product in the above-mentioned regions.

Gloria Pharmaceutical said that Tianjin Boda's promotion of methylcobalamin injection will further enrich the company's product pipeline and is expected to increase the company's operating income and profits; in addition, it will help enhance the company's professional academic promotion capabilities and lay the foundation for more product cooperation in the future.

https://finance.eastmoney.com/a/202506033420849481.html